JP2022512851A5 - - Google Patents

Info

Publication number
JP2022512851A5
JP2022512851A5 JP2021523335A JP2021523335A JP2022512851A5 JP 2022512851 A5 JP2022512851 A5 JP 2022512851A5 JP 2021523335 A JP2021523335 A JP 2021523335A JP 2021523335 A JP2021523335 A JP 2021523335A JP 2022512851 A5 JP2022512851 A5 JP 2022512851A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
composition according
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059581 external-priority patent/WO2020096915A1/en
Publication of JP2022512851A publication Critical patent/JP2022512851A/ja
Publication of JP2022512851A5 publication Critical patent/JP2022512851A5/ja
Priority to JP2024178276A priority Critical patent/JP2025004212A/ja
Pending legal-status Critical Current

Links

JP2021523335A 2018-11-05 2019-11-04 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン Pending JP2022512851A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024178276A JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862755805P 2018-11-05 2018-11-05
US62/755,805 2018-11-05
PCT/US2019/059581 WO2020096915A1 (en) 2018-11-05 2019-11-04 Dosing regimen of anti-tigit antibody for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024178276A Division JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Publications (2)

Publication Number Publication Date
JP2022512851A JP2022512851A (ja) 2022-02-07
JP2022512851A5 true JP2022512851A5 (https=) 2022-11-16

Family

ID=70611082

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021523335A Pending JP2022512851A (ja) 2018-11-05 2019-11-04 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン
JP2024178276A Withdrawn JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024178276A Withdrawn JP2025004212A (ja) 2018-11-05 2024-10-10 がんの処置のための抗ｔｉｇｉｔ抗体の投薬レジメン

Country Status (10)

Country Link
US (1) US20210403557A1 (https=)
EP (1) EP3877418A4 (https=)
JP (2) JP2022512851A (https=)
KR (1) KR20210091209A (https=)
CN (1) CN113302204A (https=)
AU (1) AU2019375409A1 (https=)
BR (1) BR112021008582A8 (https=)
CA (1) CA3118964A1 (https=)
MX (1) MX2021005236A (https=)
WO (1) WO2020096915A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202112838YA (en) 2008-04-09 2021-12-30 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
KR20230024368A (ko) * 2020-06-18 2023-02-20 제넨테크, 인크. 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
WO2022063100A1 (zh) * 2020-09-22 2022-03-31 南京圣和药业股份有限公司 抗tigit抗体及双抗体和它们的应用
WO2023018677A1 (en) * 2021-08-10 2023-02-16 Merck Sharp & Dohme Llc A therapeutic combination comprising a t1git antagonist, a pd-1 antagonist, and a chemotherapeutic agent(s)
US20250064794A1 (en) * 2021-08-10 2025-02-27 Eisai R&D Management Co., Ltd. A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib
WO2024211551A1 (en) 2023-04-06 2024-10-10 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2025128499A1 (en) * 2023-12-12 2025-06-19 Merck Sharp & Dohme Llc Combination therapy of a pd-1 antagonist and lag3 antagonist and all-trans retinoic acid or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN118671353A (zh) * 2024-05-30 2024-09-20 中国人民解放军总医院第一医学中心 用于ais诊断的生物标志物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507482UA (en) * 2013-03-15 2015-10-29 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
MD4733C1 (ro) * 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
PE20181046A1 (es) * 2015-09-25 2018-07-03 Genentech Inc Anticuerpos anti-tigit y metodos de uso
CA3025391A1 (en) * 2016-05-26 2017-11-30 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for cancer treatment
ES2965352T3 (es) * 2017-05-30 2024-04-12 Bristol Myers Squibb Co Tratamiento de tumores positivos a gen 3 de activación de linfocitos (LAG-3)
EP3746119A4 (en) * 2018-02-01 2021-11-10 Merck Sharp & Dohme Corp. METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY

Similar Documents

Publication Publication Date Title
JP2022512851A5 (https=)
JP2017514795A5 (https=)
JP2013520442A5 (https=)
JP2017501167A5 (https=)
JP2019519499A5 (https=)
JP2017533912A5 (https=)
JP2017507900A5 (https=)
JP2018527383A5 (https=)
JP2020514310A5 (https=)
JP2021513540A5 (https=)
JP2020508317A5 (https=)
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
JP2017514461A5 (https=)
JP2018070648A5 (https=)
JP2018516969A5 (https=)
JP2019515008A5 (https=)
JP2020503273A5 (https=)
JP2015532292A5 (https=)
JP2018534933A5 (https=)
JP2019506403A5 (https=)
JP2014533279A5 (https=)
RU2018111529A (ru) Комбинированная терапия для лечения рака
JP2017501157A5 (https=)
JP2018518454A5 (https=)
JP2016520082A5 (https=)